Industry Alarmed By Third-Party Audit, Registry Provisions In Draft House Bills
This article was originally published in The Gray Sheet
Executive Summary
A House subcommittee released nine pieces of draft FDA legislation June 6, including several provisions that mobilized device industry lobbyists to fight for changes
You may also be interested in...
House Panel Probes FDA Inspections Of Overseas Device Facilities
With Congress increasingly focused on improving safety checks for products imported into the United States, FDA oversight of foreign device manufacturing facilities is getting pulled into the mix
House Panel Probes FDA Inspections Of Overseas Device Facilities
With Congress increasingly focused on improving safety checks for products imported into the United States, FDA oversight of foreign device manufacturing facilities is getting pulled into the mix
FDA Technical Corrections Bill Could Address Trial Registry Requirements
Clinical trial registry requirements contained in the recently enacted FDA Amendments Act are likely to be clarified in a "technical corrections" bill in the coming weeks, device industry lobbyists say